Active-comparator new-user cohort studies with an appropriate design have consistently demonstrated dementia risk reduction with SGLT2 inhibitor users with diabetes across different regions [12,13,14,15,16,17,18,19,20]
Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
This multi-action approach helps improve glycemic control and supports weight loss
How GLP-1 Medications Work GLP-1 injections for weight loss utilize a medication that mimics a natural hormone in your body
